Dr Lal PathLabs Ltd will acquire a 70% stake in Gujarat-based SN Genelab Private Limited for up to ₹168 crore in cash, the diagnostics company said in a regulatory filing on Thursday, 24 September 2026. The deal also includes a performance-linked earn-out capped at ₹31.5 crore.
Once the transaction is complete, SN Genelab will become a subsidiary of Dr Lal PathLabs. The company expects to close the deal on or before 30 November 2026, and Dr Lal PathLabs shares are in focus on Friday.
Dr Lal PathLabs SN Genelab Deal: Key Terms
The Dr Lal PathLabs board approved the acquisition at a meeting held between 4:40 pm and 5:11 pm IST on Thursday, after market hours. The stake will be bought from SN Genelab’s existing shareholders. Because the board met after the market closed at 3:30 pm IST, Friday is the first trading session in which Dr Lal PathLabs’ share price can reflect the announcement.
| Parameter | Details |
|---|---|
| Target Company | SN Genelab Private Limited |
| Stake Acquired | 70% |
| Upfront Consideration | Up to ₹168 crore |
| Earn-Out | Performance-linked, capped at ₹31.5 crore |
| Form of Payment | 100% cash |
| Expected Completion | On or before 30 November 2026 |
| Regulatory Approvals | None required, as per the filing |
| Related-Party Transaction | No |
The filing states that no prior government or regulatory approval is needed for the deal. It also states that the transaction does not fall within the scope of related-party transactions.
What an Earn-Out Means in This Deal
An earn-out is an additional payment made to sellers only if the acquired business meets agreed performance targets after the deal. In this case, the extra payout is capped at ₹31.5 crore.
This structure means the total cost for the 70% stake could range up to about ₹199.5 crore if the full earn-out is paid. The specific targets that trigger the earn-out have not been disclosed in the details reported so far.
Earn-outs link part of the purchase price to future performance and keep the sellers invested in the business after it changes hands.
SN Genelab’s Business and Revenue Trend
SN Genelab was incorporated on 16 December 2013 in Gujarat. It provides diagnostic genomics services, which involve testing a patient’s genetic material to support diagnosis and treatment decisions.
The company has reported steady growth in turnover over the last three financial years:
| Parameter | Details |
|---|---|
| FY24 Turnover | ₹43.27 crore |
| FY25 Turnover | ₹53.36 crore, up 23.3% year-on-year |
| FY26 Turnover | ₹57.96 crore, up 8.6% year-on-year |
Growth slowed in FY26 compared with the previous year, though turnover still rose by ₹4.60 crore. Profit figures for SN Genelab were not part of the details disclosed in the filing coverage.
By simple arithmetic, the upfront price of up to ₹168 crore for 70% implies an equity value of up to about ₹240 crore for the whole of SN Genelab, before any earn-out. That is roughly 4.1 times its FY26 turnover.
Why Dr Lal PathLabs Is Buying a Genomics Business
Dr Lal PathLabs said the acquisition is aimed at strengthening its expertise in genomics and expanding its portfolio of advanced diagnostic services. Genomics testing sits at the specialised end of diagnostics, compared with routine blood and pathology tests.
The deal also gives Dr Lal PathLabs an established genomics business in Gujarat, with a three-year record of rising turnover, instead of building the capability from scratch.
This is not Dr Lal PathLabs’ first acquisition. In October 2021, the company announced the acquisition of Suburban Diagnostics along with its second-quarter results for FY22.
What It Means for Dr Lal PathLabs Shareholders
After completion, SN Genelab’s financials will be consolidated into Dr Lal PathLabs’ accounts as a subsidiary. With the 70% stake bought from existing shareholders, the remaining 30% stays outside Dr Lal PathLabs’ ownership. That 30% will be shown as a non-controlling interest in the consolidated statements.
Investors tracking the stock can watch a few specific points over the coming months:
- Completion of the transaction by the 30 November 2026 target
- Any disclosure of SN Genelab’s profitability and the earn-out conditions
- Management commentary on genomics in upcoming quarterly results
- The contribution of specialised tests to Dr Lal PathLabs’ revenue mix
The deal is a cash acquisition, so it will use part of the company’s cash resources rather than dilute existing shareholders through new shares.
Shareholders who hold the stock in a demat and trading account can follow completion updates through company filings on BSE and NSE. Those who use an investing platform can add the stock to a watchlist to track price moves around such announcements.
Key Dates for the SN Genelab Acquisition
The main date to track is 30 November 2026, the deadline set for completing the transaction. Until then, the acquisition remains pending.
Any update on completion, final consideration paid, or earn-out targets will come through a stock exchange filing by Dr Lal PathLabs.
Leave a Reply